Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Down 2.5%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) traded down 2.5% during trading on Tuesday . The stock traded as low as $11.37 and last traded at $11.53. 33,077 shares were traded during mid-day trading, a decline of 91% from the average session volume of 387,633 shares. The stock had previously closed at $11.83.

Analyst Ratings Changes

A number of research analysts have weighed in on YMAB shares. Truist Financial started coverage on shares of Y-mAbs Therapeutics in a research report on Friday, June 28th. They set a “buy” rating and a $21.00 price target on the stock. HC Wainwright lifted their target price on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a report on Monday, May 13th. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Y-mAbs Therapeutics currently has an average rating of “Hold” and a consensus price target of $17.86.

Y-mAbs Therapeutics Price Performance

The company’s 50-day simple moving average is $12.85 and its 200-day simple moving average is $12.92.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Tuesday, May 7th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The firm had revenue of $19.93 million during the quarter, compared to analysts’ expectations of $22.06 million. Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. Equities research analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.52 EPS for the current fiscal year.

Insider Buying and Selling at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 7,351 shares of Y-mAbs Therapeutics stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total transaction of $95,563.00. Following the sale, the insider now directly owns 232,681 shares of the company’s stock, valued at $3,024,853. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, insider Thomas Gad sold 7,351 shares of the stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total transaction of $95,563.00. Following the completion of the transaction, the insider now directly owns 232,681 shares in the company, valued at approximately $3,024,853. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Bo Kruse sold 31,371 shares of Y-mAbs Therapeutics stock in a transaction on Friday, May 31st. The stock was sold at an average price of $12.07, for a total transaction of $378,647.97. Following the completion of the sale, the chief financial officer now owns 210,877 shares of the company’s stock, valued at approximately $2,545,285.39. The disclosure for this sale can be found here. Insiders sold a total of 99,444 shares of company stock valued at $1,203,925 in the last ninety days. Insiders own 21.50% of the company’s stock.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Hedge funds have recently bought and sold shares of the company. Campbell & CO Investment Adviser LLC bought a new position in Y-mAbs Therapeutics during the 4th quarter worth approximately $562,000. Trexquant Investment LP lifted its stake in Y-mAbs Therapeutics by 417.5% during the third quarter. Trexquant Investment LP now owns 76,585 shares of the company’s stock worth $417,000 after purchasing an additional 61,785 shares during the last quarter. GSA Capital Partners LLP boosted its holdings in Y-mAbs Therapeutics by 208.3% in the third quarter. GSA Capital Partners LLP now owns 137,299 shares of the company’s stock worth $748,000 after purchasing an additional 92,765 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Y-mAbs Therapeutics during the fourth quarter valued at $34,000. Finally, Federated Hermes Inc. raised its holdings in shares of Y-mAbs Therapeutics by 4,708.0% during the fourth quarter. Federated Hermes Inc. now owns 44,474 shares of the company’s stock worth $303,000 after purchasing an additional 43,549 shares during the period. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.